ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M

Niagen Bioscience, Inc.

2024-Q3 EPS reported $0.02 revenue$70,472,000

Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).
Net income $1.9M ($0.02 EPS) vs net loss $1.0M ($0.01 loss) in Q3 2023.
Record Adjusted EBITDA $2.9M, up from $0.5M YoY; operating cash $32.4M.
Niagen ingredient sales $6.7M (+368% YoY); Tru Niagen sales $18.1M (+4% YoY).
Expanded Niagen+ to >100 wellness clinics; pursuing FDA IND for Ataxia Telangiectasia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.